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Introduction
Autoimmune hepatitis (AIH) is a chronic and unre-
solving hepatic parenchymal necroinflammation of
unknown cause. The disease is rare in Asian countries.
Specific circulating organ-nonspecific autoantibodies
and high serum globulin level are the main character-
istics of the disease. Three types of AIH have been
defined. The most common and typical form, type 1,
is predominant in females and seropositive for both
antinuclear antibody (ANA) and/or anti-smooth mus-
cle antibody (SMA). AIH type 2 is male-dominant and
seropositive for anti-liver/kidney microsome type 1
(anti-LKM-1) antibodies. Type 3 AIH is character-
ized by the presence of antibodies against soluble liver
antigen/hepatic pancreatic antigen (SLA-LP). The
disease spectrum can range from mild to severe. Most
patients present with nonspecific symptoms such as
nausea, vomiting, anorexia, weight loss, fatigue and
mild intermittent jaundice. However, deep jaundice is
rare in Eastern countries. The diagnosis depends on
the presence of characteristic autoantibodies and the
fulfillment of criteria proposed by the International
Autoimmune Hepatitis Group.1
Here, we report a case of type 1 AIH with the initial
and predominant presentation of hyperbilirubinemia.
Jaundice was dramatically responsive to prednisolone
treatment.
Case Report
A 48-year-old female was admitted to the gastroenterol-
ogy ward of Taipei Veterans General Hospital because
of marked jaundice. She had no history of alcohol intake,
blood transfusion or drug or Chinese herbal medicine
usage in the past 3 months. Progressive jaundice had
persisted for 2 months without a definite diagnosis at
a local hospital prior to this admission. She was alert
but appeared jaundiced. On physical examination, she
had icteric sclera, no palmar erythema, no shifting
fullness and no abdominal tenderness. On admission,
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her serum levels of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase
(ALK-P) and total bilirubin were 686 U/L (normal,
0–40 U/L), 819 U/L (normal, 5–45 U/L), 134 U/L
(normal, 10–100 U/L) and 19.2 mg/dL (normal,
0.2–1.6 mg/dL), respectively. Prothrombin time was
14.4 seconds, with international normalized ratio of
1.2 (1.0–1.2). Anti-hepatitis A immunoglobulin M
(anti-HAV IgM), hepatitis B surface antigen (HBsAg),
hepatitis B core antigen (HBcAg), anti-hepatitis B
core IgM (anti-HBc IgM), anti-hepatitis C virus
(HCV) antibody, anti-Epstein Barr virus IgM, anti-
cytomegalovirus IgM, and antimitochondria antibody
(AMA) were negative. Test for anti-SMA was positive
and ANA titer was 1:320 of speckled form. Hyper-
gammaglobulinemia (IgG) was 2,340mg/dL (normal,
751–1,560 mg/dL). The ratio of ALK-P and ALT, as
defined by the Autoimmune Hepatitis Scoring System,
was 0.19. Abdominal sonography revealed thickening
of the gallbladder wall, which was compatible with
hepatitis.
Liver needle biopsy was performed 5 days after
admission. Histology of the liver specimen showed
diffuse hepatocellular ballooning and necrosis, with
occasional giant cell transformation and bile stasis.
Mixed inflammatory cell infiltrates, including plasma
cells, eosinophils, lymphocytes and a few acidophil bod-
ies, were present in the periportal area. Cholangitis
with bile duct changes were noted (Figure 1). These
findings were compatible with AIH with diffuse lobular
compartment.
Human leukocyte antigen (HLA) typing demon-
strated a phenotype of DR4, DR14, DR52 and
DR53. The diagnosis of AIH was supported by histo-
logic findings and the criteria of the International
Autoimmune Hepatitis Group (Table 1). Steroid ther-
apy was started as soon as the diagnosis was confirmed.
The starting prednisolone dose was 50 mg/day. One
week after treatment, the biochemical markers of AST,
ALT and total bilirubin levels had dramatically improved
(Figure 2).
Liver biochemistry and bilirubin levels flared up
once due to poor drug compliance by the patient, but
both were soon restored to within normal ranges after
reinstitution of the low-dose prednisolone.
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Table 1. The International Autoimmune Hepatitis Group score of
the patient before treatment
Category Factor Score
Gender Female +2
ALK-P:AST (or ALT) 0.19 +2
IgG (upper limit of normal) 1.5× +2
ANA, anti-SMA 1:320 +3
AMA Negative
Viral marker of active infection Negative +3
Hepatotoxic drugs None +1
Alcohol None +2
Concurrent immune disease None +2
Other autoantibodies Not detected
Histologic features Interface hepatitis +3
HLA DR4+ +1
Pretreatment score 21
ALK-P = alkaline phosphatase; AST = aspartate aminotransferase; ALT =
alanine aminotransferase; IgG = immunoglobulin G; ANA = antinuclear anti-
body; SMA = smooth muscle antibody; AMA = antimitochondria antibody;
HLA = human leukocyte antigen.
A B
Figure 1. Histologic findings of the liver specimen (hematoxylin & eosin, 1,600×): (A) necrosis of liver parenchyma with plasma cell infil-
tration (solid arrow) and cholestasis (broken arrow); (B) edema in the portal tract and infiltration of plasma cells and lymphocytes
(arrows); diffuse ballooning, necrosis of hepatocytes and bile stasis with bile duct changes are shown.
Discussion
AIH is an inflammatory disease of the liver characterized
by hypergammaglobulinemia, presence of autoanti-
bodies, and elevation of liver function tests. Piecemeal
necrosis and plasma cell infiltrates are typical findings
on liver biopsy. A clinical diagnosis depends on the
exclusion of other liver diseases that resemble AIH.
The International Autoimmune Hepatitis Group estab-
lished criteria for the diagnosis of the disease.1,2 These
criteria define patients into 2 groups, as probable or
definite disease. Differentiation between the 2 diag-
noses of AIH rely mainly on the degree of serum
gammaglobulin (IgG) elevation, titers of autoantibod-
ies (ANA, SMA, anti-LKM-1), and exposure to alco-
hol, medications or infectious agents that could cause
liver injury.1,3 Appropriate immunosuppressive therapy
based on an accurate diagnosis can achieve maximum
response.
In the case we report here, the patient presented
with deep jaundice as her primary symptom. In the
typical presentation of AIH, the aminotransferase lev-
els of liver enzymes are usually elevated higher than
the levels of total bilirubin, ALK-P and γ-glutamyl
transferase, a picture that looks like viral hepatitis.
Consequently, AIH must be taken into consideration
for differential diagnosis, especially in areas endemic
for viral hepatitis. Though mild elevation of bilirubin
is a common presentation of AIH and presents in 83%
of patients, the majority of cases experience a level of
bilirubin elevation that is less than 3-fold the upper
limit of normal.4 It was reported that only 18.2% of 
a total of 22 Chinese AIH patients presented with
jaundice as the initial symptom, and the mean value of
total bilirubin was 4.8 mg/dL in the female group.5,6
The elevated bilirubin level that was over 10-fold the
upper limit of normal in the current case was extremely
rare. Some might suggest that the hyperbilirubinemia
was the consequence of biliary tract destruction sec-
ondary to severe hepatic necroinflammation. However,
hyperbilirubinemia should persist longer in that case.
The dramatic response of bilirubin level to prednisolone
treatment excluded this possibility. Serum ALK-P level
is commonly elevated (81%) in AIH cases, but high-
degree elevation is less common.7 Hypergammaglobu-
linemia in AIH is a selective elevation of IgG subclass.
This unique feature of AIH matched that of our patient
except for the marked elevation in serum total bilirubin
level.
Sometimes, AIH can have a cholestatic pattern,
which merits a thorough imaging study to rule out
biliary obstruction. In this patient, deep jaundice accom-
panied by elevated aminotransferase levels were the
main presenting symptoms. This unusual presentation
expanded the differential diagnoses to include condi-
tions such as drug hepatitis, primary biliary cirrhosis
and primary sclerosing cholangitis. This patient had no
history of drug or herbal medication abuse. Approxi-
mately 80% of patients with AIH present with sig-
nificant high titers of ANA and/or anti-SMA
autoantibodies.7,8 This patient had a raised ANA titer
and presence of anti-SMA. The absence of AMA and
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Figure 2. Clinical course of the patient. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and total
bilirubin level before and after prednisolone treatment are shown. All these biochemical markers dramatically improved after pred-
nisolone administration.
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no abnormality in the biliary system on sonography
study excluded other possibilities.
There is a strong genetic basis associated with type 1
AIH.9 The principal susceptible gene in Asians is HLA-
DR4,10 which concurs with this patient’s HLA typing.
The pretreatment score of the modified criteria of the
International Autoimmune Hepatitis Group in this case
was 21, therefore, the diagnosis of type 1 AIH was
definite.
The histologic feature of AIH is interface hepatitis.
The inflammation is confined to the periportal regions
(interface hepatitis) or may sometimes involve the entire
lobule (lobular hepatitis).11 The presence of plasma
cells is a typical feature that is abundant at the inter-
face. Rosettes of hepatocytes are common in the peri-
portal area.11 The liver pathology of this patient showed
these typical features, which enhanced the diagnostic
score.
Responsiveness to corticosteroid treatment with
marked improvement in the serum levels of amino-
transferases and total bilirubin is another practical
clue to the diagnosis of AIH. In our patient, steroid
therapy was started as soon as the diagnosis was made.
The clinical and biochemical responses were remark-
able within days. Currently, steroid therapy remains
the mainstay of therapy, and the suggested initial dosage
is prednisone 1 mg/kg/day, with a maintenance dose
of 20 mg/day in Western populations. The rate of
remission with this treatment was approximately 80%.12
On the contrary, a lower dose regimen of steroid was
instituted in Taiwanese and Singapore populations,
which demonstrated remission rates of 87.5% and
89%, respectively.5,13 The average time to remission
was shorter in the Taiwanese group.5 In the present
patient, biochemical markers returned to normal ranges
within 4 weeks with low-dose steroid treatment, and
treatment was continued for 2 years.
In conclusion, AIH is a multifaceted disease that
can mimic other causes of hepatitis indiscriminately
and respond well to steroid therapy. Cholestatic jaun-
dice is rare in AIH,10 but should not be overlooked.
Although rare, AIH should be listed in the differential
diagnosis in patients with cholestasis without a history
of drug or viral hepatitis.
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